Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

HeXun Biosciences Co., Ltd. (6986.TWO)

76.80
+1.00
+(1.32%)
As of 9:02:54 AM GMT+8. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.
NameTitlePayExercisedYear Born
Mr. Ji-Hong Huang President & Director 3.24M -- --
Ms. Yubei Liao Representative Director & Chief Administrative Officer 2.62M -- --
Yushen Lan Accounting & Finance Director -- -- --
Songyuan Chen Director of Technology & Management -- -- --

HeXun Biosciences Co., Ltd.

No. 1490, Chunri Road
6th Floor Taoyuan District
Taoyuan City, 33022
Taiwan
886 3 317 5088 https://www.hexunbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
45

Description

HeXun Biosciences Co., Ltd. engages in the research and development of stem cell and treatments in Taiwan. It provides outsourced production services; commissioned development and manufacturing services for various cells and cell derivatives; commissioned inspection; advisory; laboratory information management system; and sterile filling services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.

Corporate Governance

HeXun Biosciences Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers